Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Kalorama Reports | Stem Cells Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

Stem Cells Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.

For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:

* Stem Cell Therapeutics (Transplantation)

* Cord Blood Banking and

* Drug development

This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:

* Cardiovascular disease

* Lung disease

* Arthritis

* Incontinence

* Osteoporosis

* Diabetes

* Cancer

* Orthopedics

* Infertility

* Alzheimer’s disease

* Burns (severe)

* Lupus

* Parkinson’s disease

* Liver failure

* Multiple sclerosis

* Critical limb ischemia

* Crohn's disease

* Sickle cell disease

* Multiple myeloma

* NH lymphoma

* Leukemia

Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:

* Aastrom Biosciences

* Advanced Cell Technologies

* Brainstorm Cell Therapeutics

* Celegene

* Cord Blood America

* Cord Blood Registry

* Cryo-Cell International

* ES Cell International

* Geron

* Harvest Technologies

* Invitrogen

* Medistem

* Neostem

* Opexa Therapeutics

* Osiris Therapeutics

* Plureon

* Regenetech

* Revivicor

* Stem Cell Sciences

* StemLifeLine

* ThermoGenesis

* VetCell Bioscience

* ViaCell

Mar 1, 2008 250 Pages
Table of Contents
Price: $3,995.00 / €2,670.26

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions